SCHEMBL30309922

SCHEMBL30309922

Cc1ccncc1-c1ccncc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.46
BTK Q06187 1/20 0.46
SIRT3 Q9NTG7 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ABL1 P00519 1/20 0.45
CYP1A2 P05177 8/20 0.44
CYP2E1 P05181 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C8 P10632 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2A6 P11509 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2B6 P20813 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP17A1 P05093 8/20 0.43
MAP4K1 Q92918 1/20 0.41
AOC1 P19801 1/20 0.41
AOC3 Q16853 1/20 0.41
TDO2 P48775 1/20 0.41
CYP11B1 P15538 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15784053 1.00 LCK (0.46) LCKBTKSIRT3TDP1ABL1
SCHEMBL15771446 0.85 CCNC (0.46) SIRT3TDP1ABL1CYP1A2AOC1
SCHEMBL3421743 0.84 TDO2 (0.49) SIRT3TDP1ABL1CYP1A2CYP2E1
SCHEMBL29988790 0.84 TDO2 (0.49) SIRT3TDP1ABL1CYP1A2CYP2E1
SCHEMBL17506374 0.84 AOC1 (0.52) TDP1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4434876 0.84 GPBAR1 (0.43) LCKBTKTDP1CYP1A2CYP3A4
SCHEMBL19059572 0.80 CYP17A1 (0.46) SIRT3TDP1CYP1A2CYP2E1CYP3A4
SCHEMBL29765319 0.80
SCHEMBL295409 0.80
SCHEMBL15791344 0.80 ATR (0.42) LCKBTKSIRT3TDP1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4190786-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2023-06-07 EP disclosed
EP-3808749-B1 PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES VERTEX PHARMA (US) 2023-03-08 EP disclosed